Stockscreener 앱 받기
12.83
1.74%
0.22
시간 외 거래:
12.83
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus drops after early-stage trial data for eczema therapy - MSN
Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan
Why Corvus Pharmaceuticals (CRVS) Is Down 28.0% After Rebound‑Free Soquelitinib Phase 1 Eczema Data And What's Next - Sahm
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst CallSlideshow (NASDAQ:CRVS) 2026-05-18 - Seeking Alpha
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase - sharewise.com
Boxer Capital Management's New Stake in Corvus Pharmaceuticals: SEC Filing DetailsNews and Statistics - IndexBox
Corvus Pharmaceuticals, Inc.Common Stock (NQ: CRVS - FinancialContent
Point72, Steven A. Cohen show 0% stake in Corvus (CRVS) - Stock Titan
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40 - Moomoo
Sirenia/Alex Silverstein disclose 6.83M warrant shares for Corvus (NASDAQ: CRVS) - Stock Titan
Corvus Pharmaceuticals : CRVS SID Investor Meeting Presentation FINAL - marketscreener.com
Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart
Corvus drops on trial data for eczema therapy (CRVS:NASDAQ) - Seeking Alpha
Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk - Moomoo
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - markets.businessinsider.com
Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results - TipRanks
Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety - TradingView
Corvus (Nasdaq: CRVS) details Phase 1 soquelitinib eczema results and next trials - Stock Titan
Drug-free remissions seen after short atopic dermatitis treatment - Stock Titan
Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40 - Moomoo
CRVS PE Ratio & Valuation, Is CRVS Overvalued - Intellectia AI
TradingKey - TradingKey
Number of shareholders of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Number of shareholders of Corvus Pharmaceuticals, Inc. – TRADEGATE:C17 - TradingView
Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS - Sahm
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS) - Yahoo Finance
Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33 - Moomoo
MSN Money - MSN
Corvus: Q1 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals earnings up next as AD trial looms By Investing.com - Investing.com Australia
Corvus Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Corvus (NASDAQ: CRVS) widens loss but lifts cash to $236.7M after equity raise - Stock Titan
Corvus to show eczema data backing drug-free remission potential - Stock Titan
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cash runway to 2028 as Corvus (NASDAQ: CRVS) advances soquelitinib - Stock Titan
Corvus Pharmaceuticals earnings up next as AD trial looms - Investing.com India
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board - Sahm
Could Corvus Pharmaceuticals’ (CRVS) New Board Appointment Reframe Its Immunology Strategy And Competitive Edge? - Sahm
Corvus Pharmaceuticals (CRVS.US) will release its earnings report after the market closes on May 7. - Moomoo
0.98%
0.12%
자본화:
|
볼륨(24시간):